

## GA NCORP Quarterly News

ISSUE NO. 2 | November 2020

COVID-19 has been a major concern for most of 2020. In an effort to advance their cancer research, NCI is funding research to examine the effects of COVID-19 in cancer patients. We are proud to announce that GA NCORP is currently participating in the NCI COVID study. (<https://clinicaltrials.gov/ct2/show/NCT04387656>)

### Clinical Trial Update

#### **SURVIVING COVID-19**

**TMIST** is a randomized breast cancer screening study with over 31,000 women enrolled since inception. TMIST has been proven to be the fastest growing and highest accruing trial in NCI. Since the start of COVID-19, NCI, as well as GA NCORP, followed the CDC recommendations to discontinue screening trials. During the recovery period, beginning July 1<sup>st</sup>, GA NCORP has proven the success rate of TMIST by enrolling more patients than all NCI clinical trials combined. Kudos to the team for the great success!

#### **SUCCESS OF A CLINICAL TRIAL**

**NCI-MATCH Latest Update:** MATCH is a precision medicine cancer treatment trial that uses genomic sequencing to determine the genetic makeup of the cancer cells. According to recent data, from the NCI, approximately 12% of the 5,500 sequenced cancer patients received treatment based on molecular tumor markers. Based on the molecular alterations, 38% of patients had a marker that was investigated in one of the treatment arms. After accounting for the exclusion criteria and treatment arms having reached its limit, 18% of the sequenced cohort received the targeted treatment. Even though the most common mutations were not the most actionable, common mutation identified occurred in TP53, KRAS, and APC. NCI-MATCH continues to research the value of platform trials for patients with rare genomically driven cancers.

### STUDY OF THE MONTH

#### **EAS163 (INSIGNA) – GA NCORP is currently #1 in the nation!**

Firstline Pembrolizumab alone or in Combination with Chemotherapy in Induction/Maintenance or Post progression for Untreated Stage IV Non-Squamous NSCLC  
 (<https://clinicaltrials.gov/ct2/show/NCT03793179>)

- For patients with confirmed stage IV, non-squamous NSCLC (with measurable or non-measurable disease)
- Patients with treated brain mets are eligible
- No prior treatment for advanced disease is allowed
- Cannot have known EGFR, BRAF, ALK, or ROS1 alterations/mutations

### Top Accruing Physicians By Site

#### **NHCI**

1. Lynn Baxter, MD (138)
2. Sreekanth Reddy, MD (5)
3. Cheryl Jones, MD (3)
4. Aaron Schueneman, MD (3)
5. Jayanthi Srinivasiah, MD (3)

#### **LCRP**

1. H.A. Zaren, MD (30)
2. Sarah Gill, MD (9)
3. W. Edward Richards, MD (7)
4. John Mikell, MD (6)
5. Mark Taylor, MD (6)

#### **NGMC**

1. Charles Nash, III, MD (65)
2. Andrew Johnson, MD (1)
3. Padma Nadella, MD (1)

#### **Navicent**

1. Kristi George, MD (1)

#### **JBACC**

1. Andrew Pippas, MD (3)
2. Mukesh Kumar, MD (1)

### Upcoming Events

Check out these upcoming virtual events.

- NRG Oncology – January 28-30, 2021
- GASCO Annual Meeting – February 1, 2021  
<https://www.gasco.us/meetings-topic.php?meetingid=1028>



### **QUICK TIP for the INSIGNA Trial**

Send tissue for PDL1 testing ahead of time as it is one of the stratification factors (TPS: 1%-49% vs > 50%). If PD-L1 expression TPS is unevaluable or the testing could not be completed, the patients are not eligible.



### **Affiliate Site Highlight**

Spotlight on **Northeast Georgia Medical Center!**

Located in Gainesville, Georgia, NGMC cares for almost 3,000 new patients annually. Check out their site for ground-breaking updates on their expanded Cancer Center in Braselton! [www.nghs.com](http://www.nghs.com)